Inhibition of experimental angiogenesis of cornea by somatostatin

Graefes Arch Clin Exp Ophthalmol. 2003 Jan;241(1):63-9. doi: 10.1007/s00417-002-0591-7. Epub 2002 Dec 18.


Background: This study evaluated the inhibitory activity of somatostatin 14 on the angiogenesis of cornea in vivo.

Methods: Corneal neovascularization was induced with a pellet containing 90 ng of basic fibroblast growth factor (bFGF) in a rat corneal pocket model. Three kinds of pellets were made containing bFGF plus somatostatin (SST) 0 ng, 20 ng and 200 ng for the control group, group 1 and group 2, respectively. Neovascularization was observed biomicroscopically from day 4 to day 8, and the corneas were then examined for changes in histology. Quantitation of angiogenesis in the cornea was accomplished by caliper and image analysis.

Results: The 200-ng dose of SST showed significant inhibition of both length and area of neovascularization on day 7 (0.62+/-0.11 mm vs 1.29+/-0.16 mm, 0.50+/-0.16 mm2 vs 1.35+/-0.29mm2, group 2 vs control; P<0.05). The 20 ng of somatostatin did not demonstrate any significant inhibition of neovascularization compared with the control group.

Conclusion: Our study demonstrated that SST 14 can reduce bFGF-induced corneal angiogenesis. This shows the potential value of somatostatin in the treatment of corneal neovascularization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Animals
  • Cornea / drug effects*
  • Cornea / pathology
  • Corneal Neovascularization / chemically induced
  • Corneal Neovascularization / pathology
  • Corneal Neovascularization / prevention & control*
  • Delayed-Action Preparations
  • Disease Models, Animal
  • Fibroblast Growth Factor 2
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Somatostatin / administration & dosage*


  • Angiogenesis Inhibitors
  • Delayed-Action Preparations
  • Fibroblast Growth Factor 2
  • Somatostatin